Free Trial
NASDAQ:CYTT

Cyteir Therapeutics (CYTT) Stock Price, News & Analysis

$3.01
-0.01 (-0.33%)
(As of 03/18/2024)
Today's Range
$2.92
$3.19
50-Day Range
$3.01
$3.01
52-Week Range
$1.65
$3.19
Volume
551,300 shs
Average Volume
197,270 shs
Market Capitalization
$108.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Cyteir Therapeutics

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

CYTT Stock Price History

CYTT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive CYTT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
8/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTT
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Miscellaneous

Free Float
30,814,000
Market Cap
$108.36 million
Optionable
N/A
Beta
0.10
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Joseph S. Zakrzewski (Age 62)
    Independent Investor & Independent Chairman of the Board
    Comp: $81.5k
  • Dr. Markus F. Renschler M.D. (Age 63)
    President, CEO & Director
    Comp: $718.62k
  • Dr. Kevin Mills Ph.D.
    Co-Founder
  • Mr. David G. Gaiero (Age 46)
    CFO & Treasurer

CYTT Stock Analysis - Frequently Asked Questions

How have CYTT shares performed this year?

Cyteir Therapeutics' stock was trading at $3.01 on January 1st, 2024. Since then, CYTT stock has increased by 0.0% and is now trading at $3.01.
View the best growth stocks for 2024 here
.

How do I buy shares of Cyteir Therapeutics?

Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTT) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners